Technical Analysis for RLMD - Relmada Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| 20 DMA Resistance | Bearish | 2.33% | |
| Bollinger Band Squeeze | Range Contraction | 2.33% | |
| Narrow Range Bar | Range Contraction | 2.33% | |
| 20 DMA Resistance | Bearish | 2.68% | |
| Spinning Top | Other | 2.68% | |
| Bollinger Band Squeeze | Range Contraction | 2.68% | |
| Narrow Range Bar | Range Contraction | 2.68% | |
| 20 DMA Resistance | Bearish | 2.68% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 8 hours ago |
| 10 DMA Resistance | about 8 hours ago |
| 20 DMA Support | about 10 hours ago |
| 10 DMA Support | about 10 hours ago |
| Rose Above Previous Day's High | about 10 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/06/2024
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Disease Neuroscience Neurological Disorders Urological Disorders Neurochemistry Glutamate Drug Rehabilitation Neurotransmitters Psychiatric And Neurological Disorders N Methyl D Aspartic Acid Nmda Receptor Antagonists
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Disease Neuroscience Neurological Disorders Urological Disorders Neurochemistry Glutamate Drug Rehabilitation Neurotransmitters Psychiatric And Neurological Disorders N Methyl D Aspartic Acid Nmda Receptor Antagonists
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.2225 |
| 52 Week Low | 2.415 |
| Average Volume | 93,220 |
| 200-Day Moving Average | 3.74 |
| 50-Day Moving Average | 3.31 |
| 20-Day Moving Average | 3.02 |
| 10-Day Moving Average | 3.01 |
| Average True Range | 0.16 |
| RSI (14) | 45.65 |
| ADX | 30.95 |
| +DI | 14.44 |
| -DI | 17.89 |
| Chandelier Exit (Long, 3 ATRs) | 2.77 |
| Chandelier Exit (Short, 3 ATRs) | 2.92 |
| Upper Bollinger Bands | 3.10 |
| Lower Bollinger Band | 2.93 |
| Percent B (%b) | 0.82 |
| BandWidth | 5.54 |
| MACD Line | -0.09 |
| MACD Signal Line | -0.13 |
| MACD Histogram | 0.0351 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.19 | ||||
| Resistance 3 (R3) | 3.18 | 3.13 | 3.17 | ||
| Resistance 2 (R2) | 3.13 | 3.10 | 3.14 | 3.16 | |
| Resistance 1 (R1) | 3.10 | 3.08 | 3.12 | 3.11 | 3.16 |
| Pivot Point | 3.05 | 3.05 | 3.06 | 3.06 | 3.05 |
| Support 1 (S1) | 3.02 | 3.02 | 3.04 | 3.03 | 2.98 |
| Support 2 (S2) | 2.97 | 3.00 | 2.98 | 2.98 | |
| Support 3 (S3) | 2.94 | 2.97 | 2.97 | ||
| Support 4 (S4) | 2.95 |
